| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BJD.12941 |
| P698 | PubMed publication ID | 24606161 |
| P50 | author | Catherine H Smith | Q48208383 |
| Jonathan N. Barker | Q48208397 | ||
| Zarif K Jabbar-Lopez | Q58417738 | ||
| P2093 | author name string | T Wong | |
| A P Dhillon | |||
| C M Maybury | |||
| P2860 | cites work | Methotrexate and histologic hepatic abnormalities: a meta-analysis | Q28326451 |
| Liver Damage due to Methotrexate in Patients with Psoriasis | Q28365330 | ||
| The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up | Q31892577 | ||
| Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity | Q33841403 | ||
| Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis | Q34327755 | ||
| Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom | Q35753936 | ||
| Toward a better understanding of methotrexate | Q35775065 | ||
| Psoriasis severity and the prevalence of major medical comorbidity: a population-based study | Q37239394 | ||
| Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. | Q37306085 | ||
| Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. | Q37506748 | ||
| Psoriasis and non-alcoholic fatty liver disease. | Q37788777 | ||
| Assessment and management of psoriasis: summary of NICE guidance | Q38055469 | ||
| The association between psoriasis and dyslipidaemia: a systematic review | Q38056160 | ||
| Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies | Q38077625 | ||
| The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. | Q38098061 | ||
| Methotrexate guidelines--revised | Q40326046 | ||
| Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up | Q41507707 | ||
| Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis | Q42265254 | ||
| Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis | Q43296041 | ||
| Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury | Q45711313 | ||
| Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. | Q45949962 | ||
| Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. | Q54408977 | ||
| European S3-Guidelines on the systemic treatment of psoriasis vulgaris | Q57244449 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | methotrexate | Q422232 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 17-29 | |
| P577 | publication date | 2014-07-15 | |
| P1433 | published in | British Journal of Dermatology | Q4970191 |
| P1476 | title | Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies | |
| P478 | volume | 171 |
| Q40590985 | British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. |
| Q38780434 | Diagnosing liver fibrosis: a narrative review of current literature for dermatologists |
| Q39412233 | Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues |
| Q40837256 | Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role? |
| Q39735574 | Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors |
| Q33710680 | Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All? |
| Q34214845 | Methotrexate use and liver disease--a causal relationship? |
| Q55082101 | Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. |
| Q38612446 | Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy |
| Q35704644 | Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative stress |
| Q39128261 | Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials |
| Q50148198 | Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. |
| Q38380882 | Systemic methotrexate for the treatment of psoriasis. |
| Q50025325 | Therapeutic role of methotrexate in pediatric Crohn's disease |
| Q97645990 | Total Cumulative Dose of Methotrexate is Not the Same as Continuous Cumulative Dose: A Clinician's Perspective |
| Q36372720 | Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases |
Search more.